Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

4 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Genetic Screening For HLA-B*5701 in Patients with HIV Serious Adverse Events NCT00340080 - Genetic Screening For HLA-B*5701 Serious Adverse Events NCT00340080

- 25/04/17 - 1 modulo, 1 ItemGroup, 55 elementi, 1 linguaggio
ItemGroup: Serious Adverse Events
NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Serious Adverse Events Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Genetic Screening For HLA-B*5701 in Patients with HIV Non-serious Adverse Events NCT00340080 - Genetic Screening For HLA-B*5701 Non-serious Adverse Events NCT00340080

- 25/04/17 - 1 modulo, 1 ItemGroup, 10 elementi, 1 linguaggio
ItemGroup: Non-serious Adverse Events
NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Non-serious Adverse Events Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Serious adverse events_LAIS grass tablets by allergic rhinoconjunctivitis EudraCT-Nr. 2012-004916-79 - Documentation serious adverse events

- 28/01/16 - 1 modulo, 3 itemgroups, 17 elementi, 1 linguaggio
Itemgroups: Patient information, Serious adverse events, Medication
Study part: Documentation serious adverse events. Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Adverse events_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79Test Study - Documentation adverse events

- 28/01/16 - 1 modulo, 1 ItemGroup, 11 elementi, 1 linguaggio
ItemGroup: adverse event
Study part: Documentation adverse events. Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial